Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 11/20 | 0.42 |
| ▸ | CTSS | P25774 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3682058 | 1.00 | CA1 (0.45) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL344846 | 1.00 | CA1 (0.45) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL6684772 | 0.91 | CA1 (0.49) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL2861782 | 0.87 | CA1 (0.52) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL18428079 | 0.86 | CA1 (0.42) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL28216274 | 0.86 | CA1 (0.42) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL2385476 | 0.86 | CTSK (0.49) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL3689498 | 0.86 | CYP2D6 (0.55) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL10224759 | 0.86 | CA1 (0.45) | CA1CA2CA7CYP2D6ATM | |
| SCHEMBL4981261 | 0.86 | CTSK (0.49) | CA1CA2CA7CYP2D6ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11878965-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-01-23 | — | — | US | disclosed |
| US-20240002425-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-04 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| EP-4267587-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | Gilead Sciences, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4267562-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-6812231-B2 | INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | disclosed |
| WO-2004056750-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| US-20020107290-A1 | Benzamidine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| EP-0973517-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6410538-B2 | ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI | AJINOMOTO CO., INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | AJINOMOTO CO., INC (JP) | 2001-12-27 | — | — | US | disclosed |
| US-6288105-B1 | COMPOUNDS SUCH AS (S)-2-(4-((2-AMINO-3-HYDROXY-1-OXOPROPYL)AMINO)PHENYL)-6-HYDRO XY-3-(3-METHOXY-4-(1-PYRROLIDINYLMETHYL)BENZYL)BENZO(B)THIOPHE NE | ELI LILLY AND COMPANY | 2001-09-11 | — | — | US | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-0973517-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998048794-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107290-A1 | Benzamidine derivative | SERPINE1, SERPINC1, TFPI | CA1 3403/4885CA2 3566/4885CA7 3132/4885 |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | SERPINC1, SERPINE1, F2 | CA1 1471/4885CA2 1711/4885CA7 1748/4885 |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CA1 4873/4885CA2 2487/4885CA7 4533/4885 |
| US-20240002425-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | TLR4, TLR5, TLR9 | CA1 4012/4885CA2 864/4885CA7 1945/4885 |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CA1 4873/4885CA2 2602/4885CA7 4639/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | CA1 2579/4885CA2 3565/4885CA7 4269/4885 |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CA1 4871/4885CA2 2542/4885CA7 4573/4885 |
| US-11878965-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | CA1 2579/4885CA2 3565/4885CA7 4269/4885 |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CA1 4870/4885CA2 2601/4885CA7 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.